乾癬治療薬市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、作用機序別、投与経路別、地域別、競合別、2020-2030年

乾癬治療薬の世界市場規模は、2024年に210億6,000万米ドルとなり、2030年までCAGR 6.57％で成長し、予測期間終了時には大きな市場規模に達すると予測されています。

この市場は、乾癬の世界の罹患率の増加、進行中の治療法の進歩、より効果的で個別化された治療に対する需要の高まりによって急速に発展しています。乾癬は、赤く炎症を起こした鱗屑性の皮膚病変をもたらす慢性の自己免疫疾患であり、世界中で数百万人が罹患し、生活の質に大きな影響を及ぼしています。認知度と診断能力が向上するにつれ、乾癬の特定と治療はより一般的になってきています。治療法は多岐にわたり、外用薬、光線療法、全身薬、生物学的製剤などがあります。特に生物学的製剤は有効性と安全性を高め、治療のパラダイムを変革してきました。研究の拡大、ヘルスケア政策の支援、標的治療に対する患者の需要の増加により、乾癬治療薬市場は世界各地域で勢いを増し続けています。

市場促進要因

乾癬の有病率の増加

主な市場課題

乾癬の原因および誘因の限定的な理解

主要市場動向

生物学的製剤による治療が主流

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の乾癬治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別（生物学的製剤、低分子全身性薬剤、熱帯療法）
  • 作用機序別（TNFα阻害剤、PDE4阻害剤、インターロイキン阻害剤、その他）
  • 投与経路（経口、非経口、局所）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の乾癬治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の乾癬治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の乾癬治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の乾癬治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの乾癬治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の乾癬治療薬市場：SWOT分析

第14章 競合情勢

• Glanbia Plc
• Pfizer Inc.
• Bayer AG
• Amway Corp.
• GlaxoSmithKline plc.
• Good Health New Zealand
• The Nature's Bounty Co.
• NOW Foods
• Abbott
• Herbalife Nutrition

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Psoriasis Drugs Market has been valued at USD 21.06 billion in 2024 and is expected to grow at a CAGR of 6.57% through 2030, reaching significant market size by the end of the forecast period. This market is evolving rapidly, driven by the increasing global incidence of psoriasis, ongoing therapeutic advancements, and rising demand for more effective and personalized treatments. Psoriasis is a chronic autoimmune disorder that results in red, inflamed, and scaly skin lesions, affecting millions of people worldwide and significantly impacting quality of life. As awareness and diagnostic capabilities improve, the identification and treatment of psoriasis are becoming more prevalent. The therapeutic landscape is diverse, spanning topical agents, phototherapy, systemic drugs, and biologic therapies. Biologics, in particular, have transformed the treatment paradigm by offering enhanced efficacy and safety. With expanding research, supportive healthcare policies, and increasing patient demand for targeted treatments, the psoriasis drugs market continues to gain momentum across global regions.

Key Market Drivers

Increasing Prevalence of Psoriasis

The rising prevalence of psoriasis globally is a key driver for the market. This autoimmune condition, characterized by an overproduction of skin cells, results in painful, itchy, and inflamed patches. The likelihood of developing psoriasis increases with genetic predisposition, which is being amplified as populations grow and awareness of the disease improves. According to a 2025 NIH report, Spain saw a 43.3% increase in psoriasis cases from 2022, growing from 692,317 to 991,832. This significant rise illustrates the expanding patient base. Moreover, modern environmental and lifestyle factors-such as heightened stress, smoking, poor diet, and exposure to pollution-are contributing to the disease's growing incidence. Enhanced diagnostic practices also play a role, allowing more cases, including milder forms, to be correctly identified and treated. Collectively, these factors are intensifying the demand for innovative and effective treatment options.

Key Market Challenges

Limited Understanding of Psoriasis Causes and Triggers

One of the most significant challenges in managing psoriasis is the limited understanding of its exact causes and triggers. As a multifactorial autoimmune disorder, psoriasis involves complex interactions between genetic, environmental, and immune system factors. The variability in genetic markers among patients complicates the development of universal or targeted therapies. Additionally, triggers such as stress, infections, and certain medications vary widely from person to person, making individualized treatment approaches challenging. This lack of clarity in disease etiology hinders the development of more precise treatments and limits the potential for personalized medicine in psoriasis care. It also poses difficulties for clinicians in predicting flare-ups and selecting optimal therapeutic strategies.

Key Market Trends

Biologic Therapies Dominating Treatment Approaches

A leading trend in the Global Psoriasis Drugs Market is the rising dominance of biologic therapies. These advanced drugs, derived from living organisms, specifically target key immune system pathways responsible for psoriasis, such as cytokines and immune cell receptors. Biologics have shown superior results compared to conventional treatments, offering greater symptom relief and fewer side effects. This has led to a shift in clinical preference, especially for moderate to severe psoriasis cases. Their ability to provide sustained remission has positioned biologics as a mainstay in psoriasis management. The trend is further supported by ongoing drug development and approvals, making these therapies increasingly accessible and expanding the market for targeted biologic solutions.

Key Market Players

• Glanbia Plc
• Pfizer Inc.
• Bayer AG
• Amway Corp.
• GlaxoSmithKline plc.
• Good Health New Zealand
• The Nature's Bounty Co.
• NOW Foods
• Abbott
• Herbalife Nutrition

Report Scope:

In this report, the Global Psoriasis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Psoriasis Drugs Market, By Type of Treatment:

• Biologic Drugs
• Small Molecule Systemic Drugs
• Tropical Therapies

Psoriasis Drugs Market, By Mechanism of Action:

• TNF Alpha Inhibitors
• PDE4 Inhibitors
• Interleukin Inhibitors
• Others

Psoriasis Drugs Market, By Route of Administration:

• Oral
• Parenteral
• Topical

Psoriasis Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Psoriasis Drugs Market.

Available Customizations:

Global Psoriasis Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Route of Administrations
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Psoriasis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Treatment (Biologic Drugs, Small Molecule Systemic Drugs, Tropical Therapies)
  • 5.2.2. By Mechanism of Action (TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
  • 5.2.3. By Route of Administration (Oral, Parenteral, Topical)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Psoriasis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Treatment
  • 6.2.2. By Mechanism of Action
  • 6.2.3. By Route of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Psoriasis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Treatment
      • 6.3.1.2.2. By Mechanism of Action
      • 6.3.1.2.3. By Route of Administration
  • 6.3.2. Canada Psoriasis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Treatment
      • 6.3.2.2.2. By Mechanism of Action
      • 6.3.2.2.3. By Route of Administration
  • 6.3.3. Mexico Psoriasis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Treatment
      • 6.3.3.2.2. By Mechanism of Action
      • 6.3.3.2.3. By Route of Administration

7. Europe Psoriasis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Treatment
  • 7.2.2. By Mechanism of Action
  • 7.2.3. By Route of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Psoriasis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Treatment
      • 7.3.1.2.2. By Mechanism of Action
      • 7.3.1.2.3. By Route of Administration
  • 7.3.2. United Kingdom Psoriasis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Treatment
      • 7.3.2.2.2. By Mechanism of Action
      • 7.3.2.2.3. By Route of Administration
  • 7.3.3. Italy Psoriasis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type of Treatment
      • 7.3.3.2.2. By Mechanism of Action
      • 7.3.3.2.3. By Route of Administration
  • 7.3.4. France Psoriasis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Treatment
      • 7.3.4.2.2. By Mechanism of Action
      • 7.3.4.2.3. By Route of Administration
  • 7.3.5. Spain Psoriasis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Treatment
      • 7.3.5.2.2. By Mechanism of Action
      • 7.3.5.2.3. By Route of Administration

8. Asia-Pacific Psoriasis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Treatment
  • 8.2.2. By Mechanism of Action
  • 8.2.3. By Route of Administration
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Psoriasis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Treatment
      • 8.3.1.2.2. By Mechanism of Action
      • 8.3.1.2.3. By Route of Administration
  • 8.3.2. India Psoriasis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Treatment
      • 8.3.2.2.2. By Mechanism of Action
      • 8.3.2.2.3. By Route of Administration
  • 8.3.3. Japan Psoriasis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Treatment
      • 8.3.3.2.2. By Mechanism of Action
      • 8.3.3.2.3. By Route of Administration
  • 8.3.4. South Korea Psoriasis Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Treatment
      • 8.3.4.2.2. By Mechanism of Action
      • 8.3.4.2.3. By Route of Administration
  • 8.3.5. Australia Psoriasis Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Treatment
      • 8.3.5.2.2. By Mechanism of Action
      • 8.3.5.2.3. By Route of Administration

9. South America Psoriasis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Treatment
  • 9.2.2. By Mechanism of Action
  • 9.2.3. By Route of Administration
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Psoriasis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Treatment
      • 9.3.1.2.2. By Mechanism of Action
      • 9.3.1.2.3. By Route of Administration
  • 9.3.2. Argentina Psoriasis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Treatment
      • 9.3.2.2.2. By Mechanism of Action
      • 9.3.2.2.3. By Route of Administration
  • 9.3.3. Colombia Psoriasis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Treatment
      • 9.3.3.2.2. By Mechanism of Action
      • 9.3.3.2.3. By Route of Administration

10. Middle East and Africa Psoriasis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Treatment
  • 10.2.2. By Mechanism of Action
  • 10.2.3. By Route of Administration
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Psoriasis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Treatment
      • 10.3.1.2.2. By Mechanism of Action
      • 10.3.1.2.3. By Route of Administration
  • 10.3.2. Saudi Arabia Psoriasis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Treatment
      • 10.3.2.2.2. By Mechanism of Action
      • 10.3.2.2.3. By Route of Administration
  • 10.3.3. UAE Psoriasis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Treatment
      • 10.3.3.2.2. By Mechanism of Action
      • 10.3.3.2.3. By Route of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Psoriasis Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Glanbia Plc
  • 14.1.1. Business Overview
  • 14.1.2. Mechanism of Action Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Key Personnel
  • 14.1.5. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Bayer AG
• 14.4. Amway Corp.
• 14.5. GlaxoSmithKline plc.
• 14.6. Good Health New Zealand
• 14.7. The Nature's Bounty Co.
• 14.8. NOW Foods
• 14.9. Abbott
• 14.10. Herbalife Nutrition

15. Strategic Recommendations

16. About Us & Disclaimer